Patent · US Active

Compositions and methods for treatment of diabetic macular edema

US12084515B2 · kind B2 · utility

1Cited by

187References

10Claims

0Family size

Assignee

Takeda Pharmaceutical Company Limited · JP

Inventors

Gregory P. Conley · Arlington, US
Andrew Nixon · Hanover, US
Daniel J. Sexton · Melrose, US

Key dates

Filing date	Jun 11, 2021
Grant date	Sep 10, 2024
Priority date	—
Expiry date	Mar 31, 2042

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07K2317/92
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Disclosed herein are compositions comprising one or more antibodies that specifically bind active plasma kallikrein (e.g., human plasma kallikrein) and methods of using such compositions for the treatment of retinal diseases, such as diabetic macular edema.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.